Do newer antipsychotics have any advantages?

THIS PAGE IS UNDER CONSTRUCTION Optimum intrinsic activity at D2 receptors? It has been argued (Stahl, 2016) that antipsychotics with higher intrinsic activity at D2 receptors can be too activating, at least for some patients, e.g., aripiprazole (Abilify®). Brexpiprazole (Rexulti®) and cariprazine (Vraylar®) are, like aripiprazole, partial agonists at D2 receptors but they have a…